相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Oncolytic herpes simplex virus vectors and taxanes synergize to promote killing of prostate cancer cells
B. J. Passer et al.
CANCER GENE THERAPY (2009)
Prostate cancer: the new landscape
Judd W. Moul et al.
CURRENT OPINION IN UROLOGY (2009)
Prostate Stem Cell Antigen DNA Vaccination Breaks Tolerance to Self-antigen and Inhibits Prostate Cancer Growth
Sarfraz Ahmad et al.
MOLECULAR THERAPY (2009)
Current controversies in the treatment of high-risk prostate cancer
Robert E. Mitchell et al.
CURRENT OPINION IN UROLOGY (2008)
Oncolytic herpes virus with defective ICP6 specifically replicates in quiescent cells with homozygous genetic mutations in p16
M. Aghi et al.
ONCOGENE (2008)
Recurrent gene fusions in prostate cancer
Chandan Kumar-Sinha et al.
NATURE REVIEWS CANCER (2008)
Plasmid DNA vaccine encoding prostatic acid phosphatase is effective in eliciting autologous antigen-specific CD8+ T cells
Laura E. Johnson et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress
Ta-Chiang Liu et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2007)
Virotherapy with a type 2 herpes simplex virus-derived oncolytic virus induces potent antitumor immunity against neuroblastoma
Hongtao Li et al.
CLINICAL CANCER RESEARCH (2007)
Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy
Ta-Chiang Liu et al.
MOLECULAR THERAPY (2006)
Flip-Flop HSV-BAC: bacterial artificial chromosome based system for rapid generation of recombinant herpes simplex virus vectors using two independent site-specific recombinases
Toshihiko Kuroda et al.
BMC BIOTECHNOLOGY (2006)
Systemic oncolytic herpes virus therapy of poorly immunogenic prostate cancer metastatic to lung
S Varghese et al.
CLINICAL CANCER RESEARCH (2006)
Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers
S Varghese et al.
CANCER GENE THERAPY (2006)
Triple gene-deleted oncolytic herpes simplex virus vector double-armed with interleukin 18 and soluble B7-1 constructed by bacterial artificial chromosome-mediated system
H Fukuhara et al.
CANCER RESEARCH (2005)
Oncolytic viral therapies - the clinical experience
M Aghi et al.
ONCOGENE (2005)
HSV oncolytic therapy upregulates interferon-inducible chemokines and recruits immune effector cells in ovarian cancer
F Benencia et al.
MOLECULAR THERAPY (2005)
Induction of autoantibodies to syngeneic prostate-specific membrane antigen by xenogeneic vaccination
PD Gregor et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Xenogeneic immunization in mice using HER2 DNA delivered by an adenoviral vector
P Gallo et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Replicative oncolytic herpes simplex viruses in combination cancer therapies
DE Post et al.
CURRENT GENE THERAPY (2004)
HSV-1 therapy of primary tumors reduces the number of metastases in an immune-competent model of metastatic breast cancer
DL Thomas et al.
MOLECULAR THERAPY (2003)
A single heteroclitic epitope determines cancer immunity after xenogeneic DNA immunization against a tumor differentiation antigen
JS Gold et al.
JOURNAL OF IMMUNOLOGY (2003)
Immunogene therapy of tumors with vaccine based on xenogeneic epidermal growth factor receptor
Y Lu et al.
JOURNAL OF IMMUNOLOGY (2003)
Oncolytic herpes simplex virus vectors for cancer virotherapy
S Varghese et al.
CANCER GENE THERAPY (2002)
Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy
L Fong et al.
JOURNAL OF IMMUNOLOGY (2001)
Expression, specificity and immunotherapy potential of prostate-associated genes in murine cell lines
ME Grossmann et al.
WORLD JOURNAL OF UROLOGY (2001)
分享论文
